MYC-rearrangement within 2 years after diagnosis may affect the prognosis of patients with diffuse large B-cell lymphoma.
A new study looks into whether disease stage at diagnosis affects the occurrence and location of a second primary malignancy in DLBCL.
Prognostic signature associated with AML relapse risk potential harbors gene subsets that apply to only certain patient subgroups.
A total of 30 patients were enrolled in an expansion cohort for relapsed/refractory primary mediastinal B-cell lymphoma and received nivolumab and brentuximab vedotin.
While ibrutinib plus rituximab may improve progression-free survival in chronic lymphocytic leukemia, it is a costly option for some patients.
Delays in CAR T-cell therapy may significantly decrease gains in survival and productivity for patients with diffuse large B-cell lymphoma and pediatric acute lymphoblastic leukemia.
Researchers looked at the pre-transplant PET/CT Deauville scores of patients with relapsed or refractory diffuse large B-cell lymphoma treated with R-DHAC to see if patients with a higher score had a higher risk for treatment failure.
Researchers utilized a targeted next-generation sequencing (NGS) panel developed at Oregon Health & Science University to assess the clearance of mutations after therapy, clonal evolution at relapse, and combinations of mutations.
A new report suggests targeting the Gal9/TIM3-axis could help boost chances of complete remission in patients with acute myeloid leukemia.
The CLARITY trial looked at measurable residual disease negativity in 54 patients with relapsed or refractory chronic lymphocytic leukemia who received ibrutinib in combination with venetoclax.